Literature DB >> 26780946

Botulinum Toxin and Muscle Atrophy: A Wanted or Unwanted Effect.

Paul D Durand1, Rafael A Couto1, Raymond Isakov1, Donald B Yoo1, Babak Azizzadeh1, Bahman Guyuron1, James E Zins1.   

Abstract

While the facial rejuvenating effect of botulinum toxin type A is well known and widespread, its use in body and facial contouring is less common. We first describe its use for deliberate muscle volume reduction, and then document instances of unanticipated and undesirable muscle atrophy. Finally, we investigate the potential long-term adverse effects of botulinum toxin-induced muscle atrophy. Although the use of botulinum toxin type A in the cosmetic patient has been extensively studied, there are several questions yet to be addressed. Does prolonged botulinum toxin treatment increase its duration of action? What is the mechanism of muscle atrophy and what is the cause of its reversibility once treatment has stopped? We proceed to examine how prolonged chemodenervation with botulinum toxin can increase its duration of effect and potentially contribute to muscle atrophy. Instances of inadvertent botulinum toxin-induced atrophy are also described. These include the "hourglass deformity" secondary to botulinum toxin type A treatment for migraine headaches, and a patient with atrophy of multiple facial muscles from injections for hemifacial spasm. Numerous reports demonstrate that muscle atrophy after botulinum toxin type A treatment occurs and is both reversible and temporary, with current literature supporting the notion that repeated chemodenervation with botulinum toxin likely responsible for both therapeutic and incidental temporary muscle atrophy. Furthermore, duration of response may be increased with subsequent treatments, thus minimizing frequency of reinjection. Practitioners should be aware of the temporary and reversible effect of botulinum toxin-induced muscle atrophy and be prepared to reassure patients on this matter.
© 2016 The American Society for Aesthetic Plastic Surgery, Inc. Reprints and permission: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26780946     DOI: 10.1093/asj/sjv208

Source DB:  PubMed          Journal:  Aesthet Surg J        ISSN: 1090-820X            Impact factor:   4.283


  7 in total

1.  Botulinum toxin A-induced muscle paralysis stimulates Hdac4 and differential miRNA expression.

Authors:  Leah E Worton; Edith M Gardiner; Ronald Y Kwon; Leah M Downey; Brandon J Ausk; Steven D Bain; Ted S Gross
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

2.  Recombinant botulinum neurotoxin serotype A1 in vivo characterization.

Authors:  Cindy Périer; Vincent Martin; Sylvie Cornet; Christine Favre-Guilmard; Marie-Noelle Rocher; Julien Bindler; Stéphanie Wagner; Emile Andriambeloson; Brian Rudkin; Rudy Marty; Alban Vignaud; Matthew Beard; Stephane Lezmi; Mikhail Kalinichev
Journal:  Pharmacol Res Perspect       Date:  2021-10

3.  High Precision Use of Botulinum Toxin Type A (BONT-A) in Aesthetics Based on Muscle Atrophy, Is Muscular Architecture Reprogramming a Possibility? A Systematic Review of Literature on Muscle Atrophy after BoNT-A Injections.

Authors:  Alexander D Nassif; Ricardo F Boggio; Sheila Espicalsky; Gladstone E L Faria
Journal:  Toxins (Basel)       Date:  2022-01-21       Impact factor: 4.546

4.  Injection of high dose botulinum-toxin A leads to impaired skeletal muscle function and damage of the fibrilar and non-fibrilar structures.

Authors:  Jessica Pingel; Mikkel Schou Nielsen; Torsten Lauridsen; Kristian Rix; Martin Bech; Tine Alkjaer; Ida Torp Andersen; Jens Bo Nielsen; R Feidenhansl
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

5.  Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.

Authors:  Judith A Pijpers; Michel D Ferrari; Gisela M Terwindt
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

Review 6.  Botulinum Toxin Induced Atrophy: An Uncharted Territory.

Authors:  Mehri Salari; Soumya Sharma; Mandar S Jog
Journal:  Toxins (Basel)       Date:  2018-08-02       Impact factor: 4.546

Review 7.  Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?

Authors:  Joely Kaufman-Janette; Sue Ellen Cox; Steven Dayan; John Joseph
Journal:  Toxins (Basel)       Date:  2021-07-16       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.